Clinical activity of olaparib in urothelial bladder cancer with dna damage response gene mutations

Randy F. Sweis*, Brian Heiss, Jeremy Segal, Lauren Ritterhouse, Sabah Kadri, Jane E. Churpek, Kenisha Allen, Dawn Conway, Carolyn Marinier, Norm D. Smith, Sean P. Pitroda, Walter M. Stadler

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Scopus citations
Original languageEnglish (US)
JournalJCO Precision Oncology
Issue number2
DOIs
StatePublished - 2018
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sweis, R. F., Heiss, B., Segal, J., Ritterhouse, L., Kadri, S., Churpek, J. E., Allen, K., Conway, D., Marinier, C., Smith, N. D., Pitroda, S. P., & Stadler, W. M. (2018). Clinical activity of olaparib in urothelial bladder cancer with dna damage response gene mutations. JCO Precision Oncology, (2). https://doi.org/10.1200/PO.18.00264